1 / 23

CP Unknown

CP Unknown. Heme-10/19/2011 Kumaran Mudaliar and Girish Venkataraman Loyola University Medical Center, Pathology. What cells are these?- hematogones. What cells are the purple population? -Plasma cells. Additional plot of same case.

chacha
Download Presentation

CP Unknown

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CP Unknown Heme-10/19/2011 KumaranMudaliar and Girish Venkataraman Loyola University Medical Center, Pathology

  2. What cells are these?- hematogones What cells are the purple population? -Plasma cells

  3. Additional plot of same case

  4. Explain the gates in this tube containing CD45, CD19, CD20, kappa and lambda Primary gate CD19/SSC Light chain negative cells colored green and forwarded to show on all plots.

  5. Hematogones • Hematogones: physiologic precursors of B-cells • 70 years ago, distinct ‘lymphoid appearing cells’ in the bone marrow (BM). • ‘Hematogones’ (hematogonia, meaning ‘blood-maker’) • 662 patients • 8% pts had 5% or more of hematogones • 24.6% < 16 YO had hematogones • 6.3% > 16 YO had hematogones • MC in patients: lymphoma, marrow regenerative states, immuno cytopenias, AIDS

  6. Problem • At 5% level, they are conspicuous on marrow smear and can be confused with neoplastic lymphoblasts

  7. Reference Ranges? • No accepted reference ranges • BM examination is not performed in healthy people

  8. 3 stages of Hematogone Maturation • Early • Usually comprise a small minority, but can become expanded in regenerating marrows • No expression of CD 20 /CD34+ • Intermediate • Majority in most marrows • -CD34-/CD20 dim/CD10+ • Late • In contrast to mature B cells, Cd34-/CD20+/maintain dim CD10 . Light chain surface+

  9. Stage 1 Hematogones CD34+/CD10+ Gated on all CD19+ cells Stage 2 hematogones Dimmer CD10, CD20 het Stg 2 (red) and stg 3 (blue) Hematogones lack CD34 Stage 3 hematogones -bright CD20, dim CD10 >90% of B-cells in this case are hematogones

  10. Immunophenotype • CD 10+ • CD 19+ • CD 20+ Variable expression • CD 38+ • CD 45+ • TdT + [subset] • CD 34 + [subset] • Kappa & Lambda -

  11. Differences between hematogones and lymphoblasts • Both present in CD 45 dim gate • Hematogones: low side scatter • Consistent, highly reproducible, maturational pattern • No aberrant or asynchronous antigen expression • B-ALL: relatively higher side scatter • Phenotypic abnormalities: • Myeloid Markers: 13, 33, 15 • T-cell: 2, 5, 7 • Concurrent expression: TdT and cytoplasmicIgM; 34 and 20 ; 34 and surface light chains • Loss of antigen expression on blasts: 45 – ; 10 – [B-ALL with MLL abnlties] ; 34 – [E2A-PBX1 fusion]

  12. Even tho both may express an antigen, difference in expression patterns and levels of specific antigens exist • IF TdT: hematogones (coarsely granular / speckled) to blasts (finely granular / even distribution) • Also, hematogones have higher #’s of TdT and CD 10 molecules / cell • Leads to brighter expression on FC • Hematogones have less CD 19 molecules/ cell • Hence dimmer expression on FC

  13. BM Core Biopsies • Hematogones: dispersed throughout marrow • Blasts: small clusters (> 5 cells)

  14. Issues • Differentiation can be challenging • Left Shifted Hematogones • Early stages after BM transplantation • Anti-CD20 immunotherapy • Majority of B-ALL lack CD20 expression . • -Phenotypic change

  15. Sources • McKenna RW, et al. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001 Oct 15;98(8):2498-507

More Related